Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin G1 (IgG1) antibody, MTX-463, into a Phase II trial for the treatment of ...

Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into Phase 2 testing for idiopathic pulmonary fibrosis. Mediar said it expects to ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

The partnership aims to advance the idiopathic pulmonary fibrosis therapy into a Phase II trial. Credit: Andrey_Popov/Shutterstock. Mediar Therapeutics has entered a ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early studies have found to be safe and capable of engaging its target. Eli Lilly on ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

"This is a sad day for democracy and a sad day for our judicial system," the justice minister said in a statement. Information ...